

AD _____

Award Number: W81XWH-07-1-0039

TITLE: Deregulated Wnt Signaling in Prostate Cancer

PRINCIPAL INVESTIGATOR: Scott Houghtaling, Ph.D.

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center
Seattle, WA 98109

REPORT DATE: January 2008

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 31-01-2008		2. REPORT TYPE Annual Summary		3. DATES COVERED 1 JAN 2007 - 31 DEC 2007	
4. TITLE AND SUBTITLE Deregulated Wnt Signaling in Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07-1-0039	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Scott Houghtaling, Ph.D. Email: shoughta@fhcrc.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fred Hutchinson Cancer Research Center Seattle, WA 98109				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The PCRP Prostate Cancer Training Award has supported my training for the past 12 months. During this time, I have continued to work towards attaining a better understanding of (a) the biology of prostate cancer, (b) the biology of the Wnt/beta-catenin signaling pathway, (c) the principle and application of cutting edge techniques in modern molecular and cellular biology, and (d) the principle and application of genetically engineered mouse (GEM) models, with the intent of becoming uniquely positioned to investigate the role of Wnt/beta-catenin signaling in the initiation, progression and metastasis of spontaneous autochthonous prostate cancer and the emergence of the androgen depletion independent phenotype. In addition to this rigorous technical training, I have continued to attend weekly lab meetings, division wide Cancer Biology Seminar series, and the Pacific Northwest SPORE in Prostate Cancer meetings. In addition, I attended the PCRP's Innovative Minds in Prostate Cancer Today (IMPACT) meeting in Atlanta, Georgia.					
15. SUBJECT TERMS Wnt, Beta-catenin, mouse models, prostate cancer, imaging					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	6	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4-5
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	6
References.....	6
Appendices.....	6

Introduction:

The PCRP Prostate Cancer Training Award has supported my training for the past 9 months. During this time, I have continued to work towards attaining a better understanding of (a) the biology of prostate cancer, (b) the biology of the Wnt/beta-catenin signaling pathway, (c) the principle and application of cutting edge techniques in modern molecular and cellular biology, and (d) the principle and application of genetically engineered mouse (GEM) models, with the intent of becoming uniquely positioned to investigate the role of Wnt/beta-catenin signaling in the initiation, progression and metastasis of spontaneous autochthonous prostate cancer and the emergence of the androgen depletion independent phenotype. In addition to this rigorous technical training, I have continued to attend weekly lab meetings, division wide Cancer Biology Seminar series, and the Pacific Northwest SPORE in Prostate Cancer meetings. In addition, I attended the PCRP's Innovative Minds in Prostate Cancer Today (IMPACT) meeting in Atlanta, Georgia.

Body:

Specific aim 1: Determine the influence of enforced expression of the proto-oncogene, *Wnt3*, on epithelial cells of the mouse prostate.

We have engineered the bi-cistronic plasmid, *PB/Wnt3-IRES-Luc* (Figure 1A). We have tested the *Wnt3* coding sequence in cell culture experiments to show that expression of *Wnt3* is capable of activating the canonical Wnt signaling pathway (Figure 1B). Briefly, 293HEK cells were seeded in triplicate and transfected with *pcDNA3.1/Wnt3*, pRenilla, and pSuperTopFlash (Wnt signaling reporter plasmid kindly provided by the R. Moon lab, Seattle, WA). Cell lysates were prepared 24 hours after transfection and relative levels of Firefly Luciferase were measured as an indication of canonical Wnt signaling activity. We have also tested the androgen responsiveness of *PB/Wnt3-IRES-Luc* by measuring Luciferase expression in PC3 prostate cancer cells co-transfected with *PB/Wnt3-IRES-Luc* and *pcDNA3.1/Androgen Receptor* (AR) grown in the presence or absence of synthetic androgen (R1881) (Figure 1C). In preparation for microinjection into FVB zygotes, *PB/Wnt3-IRES-Luc* was digested with NotI/XhoI and a 4829 bp fragment containing the transgene was gel purified. We have generated 2 independent lines and analyzed them for reporter gene expression (Luciferase) using the Xenogen IVIS system (Figure 2). While the expression of Luciferase was observed in the prostate of these animals, it was not spatially restricted to this organ.

To provide better spatially restricted expression from the Probasin promoter, we reengineered our transgene construct to include 2 tandem repeats of the chicken β -globin HS4 region that functions as an insulator. This modified transgene was used for transgenesis in FVB zygotes. We observed a nearly identical pattern of Luciferase reporter expression in multiple founders with the modified transgene (data not shown).




Figure 1. Analysis of transgene construct. A. Transgene construct showing probasin (PB) promoter driving *Wnt3* transgene expression. B. Luciferase assay showing active Wnt signaling in 293HEK cells transfected with SuperTopFlash reporter plasmid and *Wnt3* coding sequence or empty vector control. C. Luciferase assay showing prostate cell specific transgene expression in PC3 prostate cancer cells. Columns represent mean $\pm$ SEM.

We believe that inappropriate expression of *Wnt3* during development may negatively select against embryos with high level of transgene expression. This is consistent with the observation of transgenic founder animals with widespread, low level expression of the luciferase reporter. To develop mice with high level, prostate specific expression of *Wnt3*/Luciferase, we have decided to engineer a knockin model. The theoretical construct is shown in Figure 3. Three copies of a strong transcriptional stop signal, flanked by lox p sites, will be inserted between the constitutively active CAG promoter (a combination of the chicken beta-actin promoter and cytomegalovirus immediate-early enhancer) and the downstream *Wnt3*/Luciferase bicistronic transgene. The entire transgene will be “knocked-in” to the ROSA locus via homologous recombination in mouse ES cells. The resulting “knock-in” mice will be crossed to ARR₂PB-Cre mice in which expression of Cre recombinase is under control of the modified Probasin promoter. Bigenic (CAG/*Wnt3*-Luciferase; ARR₂PB/Cre) mice will have the transcriptional stop signal deleted in the prostate epithelium and *Wnt3*/Luciferase expression should be restricted to epithelial cells of the mouse prostate.

Specific aim 2: Determine the influence of enforced *Wnt3* expression during tumor progression and metastasis in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

We are waiting to select the CAG/loxSTOPlox/*Wnt3*-IRES-*Luc* transgenic line with the highest spatially restricted expression of *Wnt3* prior to crossing to TRAMP.

Specific aim 3: Develop lines of reporter mice to detect activation of the *Wnt*/β-catenin pathway *in vivo* during normal development and cancer progression.

We obtained the plasmid, 16xSuperTopFlash (16xSTF), from the Moon lab (University of Washington) and re-engineered the plasmid to contain a loxp-STOPx3-loxp cassette positioned upstream of the Luciferase ORF (Figure 4). Tissue specificity for the reporter transgene will be obtained by crossing the *Wnt* reporter mice to transgenic mice with Cre recombinase driven by tissue specific promoter, (eg. ARR₂PB/Cre). We plan to test the reporter construct in a cell culture system by transfecting 293HEK cells with our modified reporter construct, pcDNA3.1/Cre, and pcDNA3.1/*Wnt3* followed by a Luciferase assay to measure activation of the reporter. The plasmid will be digested with KpnI/SalI, a 4345 bp fragment will be gel purified and prepared for microinjection.

Key Research Accomplishments: none

Reportable Outcomes: none




Figure 2. Imaging of PB/*Wnt3*-IRES-Luciferase mice. Mice were anesthetized with a mixture of 1.5% isoflurane/air. D-luciferin was i.p. injected at 25 mg/kg mouse body weight. Ten minutes after injection, mice were imaged with an IVIS Imaging System™ (Xenogen) with continuous isoflurane exposure. [L to R] Neg. control, founder, Pos. control (EZC).




Figure 3. Knock-in construct showing three copies of a strong transcriptional stop signal, flanked by lox p sites, will be inserted between the constitutively active CAG promoter (a combination of the chicken beta-actin promoter and cytomegalovirus immediate-early enhancer) and the downstream *Wnt3*/Luciferase bicistronic transgene. Flanking arms, used for homologous recombination into ROSA locus, are not shown.

Conclusions:

The results of this work should support or refute the hypothesis that enforced expression of *Wnt3* is sufficient to drive tumorigenesis in the mouse prostate and may provide support for *Wnt3* in metastatic disease. A quantitative increase in the GU weight of bigenic (CAG/loxSTOPlox/*Wnt3*-IRES-*Luc* x TRAMP) animals compared to TRAMP mice would support the central hypothesis that deregulated Wnt signaling can promote prostate cancer in the mouse.

Furthermore, an increase in the frequency or size of osteoblastic bone metastases in bigenic mice compared to age matched TRAMP mice would support the hypothesis that activated Wnt signaling in tumor cells can promote the formation of bone metastases.

We continue to generate CAG/loxSTOPlox/*Wnt3*-IRES-*Luc* knock-in mice. Founder animals will be imaged at 12, 18, and 24 weeks using a Xenogen IVIS to detect Luciferase expression. Prostates from transgenic mice will be analyzed for cell proliferation, apoptosis, changes in morphology and pathology. The best expressing lines will be crossed to TRAMP mice.

References: none

Appendices: none




Figure 4. The Wnt Reporter plasmid has been modified to contain a Lox-STOPx3-Lox cassette to provide tissue specificity.